NASDAQ:CRBU Caribou Biosciences Q3 2024 Earnings Report $1.24 -0.01 (-0.80%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$1.28 +0.04 (+3.63%) As of 09/25/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Caribou Biosciences EPS ResultsActual EPS-$0.38Consensus EPS -$0.44Beat/MissBeat by +$0.06One Year Ago EPSN/ACaribou Biosciences Revenue ResultsActual Revenue$2.02 millionExpected Revenue$3.37 millionBeat/MissMissed by -$1.35 millionYoY Revenue GrowthN/ACaribou Biosciences Announcement DetailsQuarterQ3 2024Date11/6/2024TimeAfter Market ClosesConference Call DateWednesday, November 6, 2024Conference Call Time12:30PM ETUpcoming EarningsCaribou Biosciences' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Caribou Biosciences Earnings HeadlinesContrasting BioStem Technologies (OTCMKTS:BSEM) and Caribou Biosciences (NASDAQ:CRBU)September 26 at 4:59 AM | americanbankingnews.comCaribou Biosciences, Inc. (NASDAQ:CRBU) Receives Consensus Rating of "Moderate Buy" from BrokeragesSeptember 19, 2026 | americanbankingnews.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain. | InvestorPlace (Ad)Caribou Biosciences (NASDAQ:CRBU) Downgraded by Wall Street Zen to "Sell"September 19, 2026 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Pharvaris (PHVS), Caribou Biosciences (CRBU) and Aveanna Healthcare Holdings (AVAH)August 15, 2026 | theglobeandmail.comCaribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 13, 2026 | globenewswire.comSee More Caribou Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Caribou Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Caribou Biosciences and other key companies, straight to your email. Email Address About Caribou BiosciencesCaribou Biosciences (NASDAQ:CRBU) is a clinical-stage biotechnology company developing genome-edited cell therapies for the treatment of cancer. The company uses its CRISPR-based chRDNA™ technology platform to make targeted genetic modifications to immune cells, with the goal of creating more effective and scalable therapies. Caribou’s pipeline has focused primarily on allogeneic, or “off-the-shelf,” CAR-T cell therapies. Its investigational programs have included CB-010, an anti-CD19 CAR-T therapy designed for certain blood cancers, as well as additional programs targeting diseases such as multiple myeloma and acute myeloid leukemia. These therapies are intended to use donor-derived cells that are edited to improve their function and reduce the risk of immune rejection. Founded in 2011 and headquartered in Berkeley, California, Caribou was co-founded by Nobel Prize-winning scientist Jennifer Doudna. Rachel Haurwitz, Ph.D., has served as the company’s president and chief executive officer. Caribou conducts research and clinical development activities in the United States and collaborates with biotechnology and pharmaceutical organizations to advance its genome-editing platform and therapeutic candidates.View Caribou Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/21 - 09/25Costco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic ProblemDarden Restaurants Serves Up Fresh Catalysts for a Stock Price RallySoFi Is Bypassing the Banking Bottleneck With Stablecoin SettlementSuper Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
